USMLE/COMLEX 2 - Myocardial Infarction Symptoms, Diagnosis, & Treatment

Here are key facts for USMLE Step 2 CK & COMLEX-USA Level 2 from the Myocardial Infarctions: Diagnosis & Treatment tutorial, focusing on clinical management and treatment decision-making that are essential for these exams. See the tutorial notes for further details and relevant links.

• --

1. Geographic trends: Incidence of myocardial infarctions is declining in high-income countries but rising in middle- and low-income countries. 2. Demographic patterns: Within the United States, MI incidence after age 35, from highest to lowest: Black males > Black females > White males > White females. 3. Gender differences: First MI occurs approximately 10 years earlier in men than women, possibly related to risk factors such as smoking and hyperlipidemia. 4. Mortality disparities: Despite overall declining rates, mortality remains higher in women than male peers, especially for young and/or minority women. 5. Major modifiable risk factors: Dyslipidemia, diabetes mellitus, hypertension, smoking (including e-cigarettes), obesity, psychosocial stress, alcohol consumption, poor diet (low in fruits and vegetables). 1. Presentation patterns:

• Prodromal symptoms: Days, weeks, or months prior to the acute event
• Acute symptoms: Experienced at the time of the event
• Silent MI: No noticeable symptoms

2. Classic presentation: Chest pain/angina variably described as dull, sharp, squeezing, pressure, or discomfort, often radiating to arms, neck, jaw, or back. 3. Associated symptoms: Gastrointestinal issues (nausea, vomiting, indigestion), extreme fatigue, sleep disturbances, headaches, dizziness, lightheadedness, shortness of breath (dyspnea), anxiety, sense of impending doom. 4. Atypical presentations: Not all patients experience angina—absence of chest pain and/or young age often leads to missed or delayed diagnosis with worse outcomes. 5. Awareness gap: Many patients, especially women, are unaware of risk factors and symptoms—a significant obstacle to prevention and treatment. 1. Definition: Myocardial infarction is defined as myocardial injury with ischemia. 2. ECG timing: Should be administered as soon as possible when MI is suspected, with serial ECGs to observe evolution of the infarction. 3. ECG classification: Distinguishes between ST-segment elevated (STEMI) or Non-ST elevated (NSTEMI) myocardial infarctions, which influences treatment strategies. 4. ECG interpretation:

• Q-wave abnormalities may indicate size/location of current MI or evidence of prior MI
• Lateral infarction: Leads I and aVL; left circumflex artery
• Apical infarction: Leads V5 and V6; left circumflex or right coronary arteries
• Anterior infarction: Leads V3 and V4; left anterior descending artery
• Anteroseptal infarction: Leads V1 and V2; proximal left anterior descending artery
• Inferior infarction: Leads II, aVF, and III; right coronary artery or left circumflex artery (in ~10% with left dominance)
• Right ventricular infarction: Requires additional leads V3R through V6R
• Posterolateral infarction: Requires additional leads V7-V9; right coronary or left circumflex artery

5. Cardiac biomarkers:

• Cardiac troponin is key to diagnosis
• Help distinguish between NSTEMI (rising/falling troponin) and unstable angina (normal troponin)
• Both cardiac troponin I and CK-MB peak within 24 hours of MI and fall to normal levels over time

1. Time-critical approach: Treatment should begin as soon as possible, ideally even before hospital arrival, to reduce the extent of myocardial necrosis. 2. Pre-hospital treatment:

• Oxygen administration when oxygen saturation is less than 90%
• Aspirin for antiplatelet effects
• Nitrates for chest pain (morphine if nitrates ineffective)

3. Reperfusion strategies:

• Based on MI classification and severity
• STEMI: Emergency PCI recommended; if unavailable, immediate fibrinolytics
• NSTEMI: Unstable/complicated cases require immediate PCI/CABG; uncomplicated cases may wait longer with possible medical management only
• Fibrinolytics generally not recommended for NSTEMI (risks outweigh benefits)

4. Pharmacotherapy:

• Antiplatelets: Aspirin, clopidogrel, or others
• Anticoagulation: Unfractionated or low molecular weight heparin
• Anti-ischemic: Beta-blockers or calcium-channel blockers
• Plaque stabilization: Statins, ACE inhibitors

5. Long-term management: Risk factor modification through improved diet, exercise, and medications for hypertension and hyperlipidemia. 1. Disease progression: MI is an important cause of heart failure, which is itself a significant cause of death. 2. Risk factor control: Aggressive modification of modifiable risk factors improves long-term outcomes. 3. Timing of intervention: Earlier reperfusion associated with better myocardial salvage and prognosis. 4. Demographic factors: Higher mortality in women, especially young and/or minority women. 5. Patient education: Awareness of symptoms and risk factors significantly impacts prevention and treatment outcomes.

• --

1. Atypical presentations: Not all patients experience classic angina—maintain high index of suspicion despite absence of chest pain. 2. Radiation patterns: Pain may radiate from chest to arms, neck, jaw, or back—radiation patterns help confirm diagnosis. 3. Non-cardiac symptoms: Gastrointestinal issues, fatigue, headaches, dizziness, and anxiety may be predominant or only symptoms. 4. Prodromal recognition: Symptoms days to months before acute MI may include fatigue, sleep disturbances, or vague discomfort. 5. Risk of missed diagnosis: Young patients and those without chest pain often experience delayed diagnosis with worse outcomes. 1. Serial assessment: ECGs should be repeated frequently to observe evolution of infarction patterns. 2. STEMI vs. NSTEMI distinction: Critical treatment decision point based on ECG findings. 3. Lead group interpretation: Different lead sets reflect specific coronary territories:

• Anterior/septal (V1-V4): Left anterior descending artery
• Lateral (I, aVL, V5-V6): Left circumflex artery
• Inferior (II, III, aVF): Right coronary artery or left circumflex

4. Additional leads: Right ventricular (V3R-V6R) and posterior (V7-V9) infarctions require extended lead sets. 5. Q-wave significance: May indicate size/location of current MI or evidence of prior MI. 1. Diagnostic hierarchy: Cardiac troponin is the preferred biomarker for MI diagnosis. 2. Temporal pattern: Both troponin and CK-MB peak within 24 hours of MI onset. 3. Differential diagnosis: Only NSTEMI (not unstable angina) shows rising/falling troponin levels. 4. Serial measurements: More valuable than single determinations for diagnosis. 5. Integration with clinical findings: Always interpret biomarkers within context of symptoms and ECG findings. 1. STEMI management: Emergency PCI recommended; if unavailable, immediate fibrinolytic therapy. 2. NSTEMI approach: Risk stratification guides timing of intervention—unstable patients need immediate intervention. 3. Pre-hospital therapy initiation: Early oxygen (when indicated), aspirin, and nitrates can limit infarct size. 4. Fibrinolytic restrictions: Generally not recommended for NSTEMI due to risk/benefit ratio. 5. Comprehensive medication approach: Combination of antiplatelets, anticoagulants, beta-blockers, statins, and ACE inhibitors. 1. Women: Higher mortality rates, more atypical presentations, first MI approximately 10 years later than men. 2. Minority patients: Black males have highest incidence after age 35, followed by Black females. 3. Young patients: Often experience missed or delayed diagnosis due to low clinical suspicion. 4. Elderly: May present with dyspnea or fatigue rather than chest pain. 5. Patient education needs: Many patients, especially women, lack knowledge about risk factors and symptoms—education is crucial.

• --

Below is information not explicitly contained within the tutorial but important for USMLE Step 2 CK & COMLEX Level 2. 1. TIMI Risk Score: Predicts 14-day outcomes in ACS patients. 2. GRACE Risk Score: Predicts in-hospital and 6-month mortality. 3. HEART Score: Stratifies chest pain patients in the emergency department. 4. CRUSADE Score: Assesses bleeding risk in ACS patients. 5. DAPT Score: Guides duration of dual antiplatelet therapy after PCI. 1. P2Y12 inhibitor selection: Clopidogrel vs. ticagrelor vs. prasugrel based on patient factors. 2. Anticoagulation options: UFH, LMWH, fondaparinux, or bivalirudin based on clinical scenario. 3. Early conservative vs. early invasive strategy: Decision-making for NSTEMI/UA patients. 4. Culprit-only vs. complete revascularization: Strategies for multivessel disease. 5. Optimal timing of intervention: Immediate vs. early vs. delayed based on risk stratification. 1. Cardiogenic shock: Early recognition, hemodynamic support, and revascularization. 2. Mechanical complications: Diagnosis and management of papillary muscle rupture, ventricular septal defect, free wall rupture. 3. Arrhythmias: Management of post-MI ventricular arrhythmias and conduction disturbances. 4. Right ventricular infarction: Special considerations including volume loading. 5. Heart failure: Recognizing and managing systolic and diastolic dysfunction. 1. Cardiac rehabilitation: Evidence-based programs improving outcomes. 2. Secondary prevention targets: Goals for lipids, blood pressure, diabetes, and smoking cessation. 3. Medication adherence strategies: Improving compliance with life-saving therapies. 4. Return to activities: Guidance for driving, sexual activity, exercise, and work resumption. 5. Depression screening: Associated with worse outcomes if untreated. 1. Cocaine-associated MI: Unique management considerations. 2. Perioperative MI: Recognition challenges and management differences. 3. Pregnancy-associated ACS: Management modifications for maternal/fetal safety. 4. Type 2 MI: Supply-demand mismatch without acute plaque rupture. 5. MINOCA (MI with Non-Obstructive Coronary Arteries): Diagnostic approach.